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Phosphodiesterase type-5 (PDE-5) inhibitors are novel and important options for the treatment of pulmonary arterial
hypertension (PAH). Therefore, we aimed to examine eﬀects of vardenaﬁl, a PDE-5 inhibitor, on the pulmonary arteries isolated
from rats with monocrotaline- (MCT-) induced pulmonary hypertension. MCT (60mg/kg) or its vehicle was administered by
a single intraperitoneal injection to 6-week-old male Sprague Dawley rats. Rats were sacriﬁced 21 days after MCT injection,
and the main pulmonary arteries were isolated and then mounted in 20mL organ baths. Concentration-response curves for
vardenaﬁl (10−10–10−5 M) were constructed in phenylephrine- (Phe-) precontracted rings. PAH caused marked rightward shift in
the curves to vardenaﬁl whereas maximal responses were not aﬀected. Inhibition of NO synthase (L-NAME, 10−4 M) or guanylyl
cyclase (ODQ, 10−5 M) caused similar attenuation in responses evoked by vardenaﬁl. Moreover, contraction responses induced by
CaCl2 (3×10−5–3×10−2 M)weresigniﬁcantlyreducedinconcentration-dependentmannerbyvardenaﬁl.Inconclusion,vardenaﬁl
inducedpulmonaryvasodilatationviainhibitionofextracellularcalciumentryinadditiontoNO-cGMPpathwayactivation.These
results provide evidence that impaired arterial relaxation in PAH can be prevented by vardenaﬁl. Thus, vardenaﬁl represents a
valuable therapeutic approach in PAH besides other PDE-5 inhibitors.
1.Introduction
Pulmonary arterial hypertension (PAH) is a severe disease
with a poor prognosis. In untreated patients, there is a
progressive increase in pulmonary vascular resistance that
leads to intractable right ventricular failure and premature
death [1]. The median period of survival after diagnosis is
about 2-3 years [2]. Despite recent major improvements in
symptomatic treatments, no current treatment cures this
devastataing condition [3]. Therefore, a novel therapeutic
strategy for pulmonary hypertension is desirable.
The pathogenesis of PAH is multifactorial [4]. Besides
vasoconstriction, endothelial cell dysfunction was also
thought to play integral role in the pathogenesis of PAH [5].
This endothelial dysfunction is characterized by an over-
production of vasoconstrictors, proliferative factors, such as
endothelin-1, and a reduction of vasodilators, antiprolifer-
ative factors, such as prostacyclin and nitric oxide (NO).
The potent vasodilator and antiproliferative activity of NO
is mediated via its second messenger, cyclic guanosine
monophosphate(cGMP),inpulmonarysystem[6].Intracel-
lular cGMP is rapidly inactivated to GMP by the activity of
cyclic nucleotide phosphodiesterases (PDEs) [7]. Inhibition
of the cGMP-speciﬁc phosphodiesterase type 5 (PDE-5)
leads to an accumulation of cGMP enhancing the action of
NO. Within the pulmonary circulation, PDE-5 is the most
abundantly expressed isoform and appears to be upregu-
lated in PAH [8–10]. Moreover, Preston et al. reported an
interesting clinical study of patients with acute and chron-
ic pulmonary hypertension in which the speciﬁc PDE-5
inhibitor, sildenaﬁl, is a potent acute pulmonary vasodilator
and addition of inhaled nitric oxide potentiates these eﬀects
[11]. Also they concluded that sildenaﬁl is well tolerated in
these patients. Recently, another PDE-5 inhibitor, tadalaﬁl,
was also granted regulatory approval on the basis of the
demonstration of favorable eﬀects on exercise capacity and2 The Scientiﬁc World Journal
qualityoflifeandimprovementsintimetoclinicalworsening
[12].
To the best of our knowledge, studies investigating the
eﬃcacy of vardenaﬁl to treat PAH are still limited to few case
reports and clinic studies [13, 14]. This speciﬁc PDE-5 in-
hibitor has not yet undergone an extensive in vitro pharmal-
ogical study in pulmonary hypertension model. Therefore,
we aimed to explore the eﬀects of vardenaﬁl in monocro-
taline-induced pulmonary hypertension and investigate the
underlying mechanisms in these eﬀects.
2.MaterialandMethods
This study was approved by the Animal Ethics Committee of
Akdeniz University Medical Faculty.
2.1. Drugs. Vardenaﬁl was provided by Bayer Health Care
AG, Leverkusen, Germany. Acetylcholine (Ach), ethylene
glycol tetraacetic acid (a chelator agent for calcium ion,
EGTA), Nω-nitro-L-arginine methyl ester (nitric oxide syn-
thase inhibitor, L-NAME), 1H-[1,2,4]oxadiazolo [4,3,
-a]quinoxalin-1-one (guanylyl cyclase inhibitor, ODQ),
phenylephrine (Phe), and monocrotaline (MCT) were pur-
chased from Sigma-Aldrich (St. Louis, MO). Stock solutions
were prepared in deionized water, except vardenaﬁl and
ODQ, which were prepared in dimethyl sulfoxide and stored
in aliquots at −20◦C; dilutions were made in deionized water
immediately before use. The ﬁnal concentration of dimethyl
sulfoxide did not exceed 0.1%. Preliminary experiments
ascertained the lack of response to either vehicle in the
concentrations employed.
2.2. Monocrotaline-Induced Pulmonary Hypertension Model.
Monocrotaline is a member of the alkaloid family of plant
toxins that induces a delayed, yet progressive vascular injury
resulting in pulmonary hypertension in rats, dogs, and
monkeys [15, 16]. It is recognized that the initial reaction
to MCT-induced pulmonary hypertension is injury to the
endothelial cells that precedes media hypertrophy in small-
size pulmonary arteries and leads to an increase in pul-
monary artery disease. The MCT-induced rat model has
been widely used as an experimental model of pulmonary
hypertension [17].
MCT was dissolved in 1.8mL 1M HCl, and 3-4mL of
distilled water was added, as described previously [18]. This
solution was adjusted to pH 7.4 with 1M NaOH and ﬁlled
up to 15mL by distilled water. The animals were divided
into 2 groups: group 1 received vehicle solution (as control
group, n: 20); group 2 (n: 20) received monocrotaline. MCT
(60mg/kg) or its vehicle was administered to 6-week-old
male Sprague Dawley rats (180–210g) as a single intraperi-
toneal injection. Rats were housed with a 12:12 light-dark
cycle and given water and standard rat chow ad libitum. All
experiments were carried out 21 days after the administra-
tion.
2.3. Tissue Preparations. After 21 days, each animal was
anesthetized with pentobarbital (45mg/kg). The heart and
lungs were removed by en bloc resection. Right and left main
pulmonary arteries were dissected and harvested for vascular
reactivity. After removal of the arteries, right ventricle (RV)
and left ventricle with septum (LV+S) were separated and
weighed. Also in some animals both from control (n: 15) and
MCT-treated(n:16)groups,therightventricle,leftventricle,
main pulmonary arteries, and the inferior lobes of the lungs
ﬁxed in 10% buﬀered formalin embedded in paraﬃnf o r
light microscopy and histopathological examinations.
2.4. Histopathological Examination. Left and right lungs of
rats were removed from the thoracic cavity, and histological
specimens were ﬁxed overnight by instillation of 10%
buﬀered formalin into the airways and vascular structures.
And then, representative cross-sections of the lungs which
include the peripheral and the central pulmonary arteries
were sampled and embedded in paraﬃn blocks. Serial
sections (5-μm-thick) were prepared and stained with hema-
toxylin and eosin for the assessment of vascular pathology.
Pulmonary arteries were identiﬁed as vessels which had two
clearly deﬁned elastic laminas. SAMBA TPS Version 5.04,
1999 was used to assess the pulmonary arteries by the same
pathologist, from Akdeniz University School of Medicine
Department of Pathology. This observer was unaware of
the groups. The percent wall thickness (WT %) of arteries
(diameter; 15–150μm) was calculated by using the following
formula as described previously [19, 20]: WT% = 2 ×
WT/external diameter (ED) × 100. The thickness of medial
wall (WT) was measured under the microscope as the dis-
tancebetweentheexternalandinternalelasticlamina,asseen
with the use of a calibrated eyepiece. ED was measured as
the diameter of external lamina. For each rat, ∼20–25 vessels
were counted, and an average was calculated. The vessels that
were close to round or oval in shape were measured. Medial
WT and the ED measurements were made at several points
of each vessel, and an average was calculated.
2.5.VascularReactivityStudies. Experimentswereconducted
on isolated main left and right pulmonary arteries. Main
pulmonary artery branches were rapidly removed, gently
cleaned of fat and connective tissues taking care not to
damage the endothelium and cut into rings of about 3mm
then carefully suspended by two stainless-steel clips passed
through the vessel lumen in a 20mL organ bath containing
Krebs solution (in mM: NaCl 136.9, KCl 5.4, CaCl2 1.5,
MgCl2 1.0 and glucose 5.5.) at 37◦C, and was continuously
aerated with 95% O2 and 5% CO2 to obtain a pH of 7.4.
Isometric tension was continuously measured with an iso-
metric force transducer (FDT-05 Force Displacement Trans-
ducer, BioPac), connected to a computer-based data acqui-
sition system (MP30 Transducer Data Acquisition System,
B i o P a c ) .T h et i s s u ew a se q u i l i b r a t e df o r6 0 m i nu n d e ra
resting tension of 1g. During this time, Krebs solution was
replaced every 15 minutes with fresh solution. After the 1
hour equilibration period, pulmonary rings were challenged
with 80mM KCl (the same composition as Krebs’ solution
with NaCl replaced by equimolar KCl) to check tissue
viability. Next, the endothelial integrity of the preparations
was determined by verifying the responsiveness to ACh
(10−6 M) in vessels precontracted with Phe (10−6 M). RingsThe Scientiﬁc World Journal 3
Table 1: Eﬀects of monocrotaline treatment on rat body weight
and cardiac weight. Results are expressed as mean ± s.e.mean.
∗Signiﬁcantly diﬀerent from control rat at P<0.05. Number
of animals is indicated in parentheses. BW (0 days): body weight
before injection; BW (21. day): body weight at 21 days after
injection; LV+S: wet weight of left ventricle plus septum; RV, wet
weight of right ventricle; RV/ LV+S: ratio of RV to LV + S.
Control (n = 20) MCT (n = 20)
BW (0 day, gr) 195 ± 18 170 ± 3
BW (21.day, gr) 317± 15 225 ± 3∗
RV/BW (gr/kg) 0.57 ± 0.02 1.15 ± 0.03∗
RV/LV + S 0.23 ± 0.01 0.59 ± 0.01∗
were then washed several times to restore tension to the
baseline level.
In the ﬁrst set of experiments, concentration-response
curves (10−10–10−5 M) for vardenaﬁl were constructed in
precontracted (Phe, 10−6 M) control or pulmonary hyper-
tensive rat pulmonary artery rings in the absence or in
the presence of L-NAME (10
−4 M) or ODQ (10
−5 M). One
concentration-response curve to vardenaﬁl was obtained in
each segment. Hence, control rings (treated with the appro-
priated vehicle) were run in parallel with experimental rings.
The second set of experiments was performed using nomi-
nallyCa2+-freemedium(containing0.1mMEGTAtochelate
trace Ca2+) and consisted of concentration-response curves
to CaCl2 (3 × 10−5–3 × 10−2M) obtained in the absence or
in the presence of vardenaﬁl (10−7–10−6M) in pulmonary
artery rings taken from pulmonary hypertensive group.
2.6. Statistical Analysis. Experimental values of relaxation or
contraction were calculated relative to the maximal changes
from the contraction produced by Phe and KCl, respectively,
taken as 100% in each tissue. In order to evaluate the eﬀects
of vardenaﬁl; maximum response (Emax), the contraction for
a half maximal response (EC50), and pD2 values were calcu-
lated. These values were calculated from the concentration-
response curve obtained in each experiment, as predicted
from the Scatchard equation for drug receptor interaction.
Data are shown as the percentage of relaxation of n experi-
ments, expressed as the mean ± S.E.M. Data were analyzed
by two-way ANOVA for multiple comparisons followed by
Bonferroni post hoc test. P<0.05 was considered to indicate
signiﬁcance. A program package was used for the statistical
analysis of all data (GraphPad Instat, 1997, version 3.00;
GraphPad Software Inc., San Diego, CA).
3. Results
3.1. Eﬀects of Monocrotaline on Rat Cardiac Weight and
Pulmonary Arteries Morphology. As shown in Table 1,b o d y
weight was signiﬁcantly decreased in the MCT-treated group
after 21 days of administration. Moreover, the ratios of RV
weight to body weight and RV weight to LV+S weight were
increased in MCT-treated rats, suggesting the occurrence of
right ventricular hypertrophy. Furthermore, the thickness of
Table 2: Monocrotaline-induced morphometric changes in pul-
monary arteries. Results are expressed as mean ± s.e. mean.
∗Signiﬁcantly diﬀe r e n tf r o mc o n t r o lr a ta tP<0.05. Number of
animals is indicated in parentheses. WT: media wall thickness; ED:
external diameter.
Control (n = 15) MCT (n = 16)
WT (μ)9 . 7 ± 0.5 19.2 ± 1.2∗
ED (μ)8 4 ± 69 5 ± 5
% WT 21.1 ± 1.2 43.1 ± 1.1∗
(a)
(b)
Figure 1: Pulmonary arteries were demonstrated in lungs from
control group (a) and from the rat with monocrotaline-induced
pulmonary hypertension (b).
the medial wall (WT) and the value of WT% were signifi-
cantly increased in pulmonary hypertensive group as com-
pared with control (Table 2) (Figures 1(a) and 1(b)).
3.2. Vascular Reactivity Studies. Vardenaﬁl (10−10–10−5 M)
induced concentration-dependent relaxation response (pD2
8.53 ± 0.04). In pulmonary hypertensive group, the relax-
ations induced by vardenaﬁl was signiﬁcantly attenuated, as
evidenced by the marked rightward shifts (pD2 6.02 ± 0.03)
(Figure 2). Interestingly, maximal response of relaxation to
vardenaﬁlwasnotaﬀectedbythedevelopmentofpulmonary
hypertension. Experiments in L-NAME (10
−4M) and ODQ
(10
−5M) were used to verify the involving of the NO/cGMP
pathway in PDE-5 inhibitor-induced relaxations. L-NAME
or ODQ were added to the organ bath 20min before
precontractionwithphenylephrine.Incubationsresultedina
signiﬁcant reduction in relaxation responses both in control4 The Scientiﬁc World Journal





























Figure 2: Concentration- response curves (10−10–10−5 M; n = 15)
to vardenaﬁl in control and pulmonary hypertensive rat pulmonary
artery rings contracted by phenylephrine (10
−6 M). Experimental
values were calculated relative to the maximal changes from the
contraction produced by phenylephrine in each tissue, which was
taken as 100%. ∗P<0.05 as compared with control.
and pulmonary hypertensive group rats and caused marked
rightward shifts in the curves to vardenaﬁl. The maximum
responses of vardenaﬁl were not signiﬁcantly change in the
absence or presence of these incubations (Figures 3(a) and
3(b)).
ThesecondsetofexperimentwasperformedinCa+2-free
Krebs solution containing EGTA. Vardenaﬁl (10−7–10−6 M)
concentration dependently inhibited contractions evoked by
CaCl2 (3 × 10−5–3 × 10−2M) with reducing the maximum
response to CaCl2 (Figure 4).
4. Discussion
This is the ﬁrst analysis of the pharmacological proﬁles of
speciﬁc PDE-5 inhibitor vardenaﬁl, in the rat MCT-induced
pulmonary artery hypertension model. In our study, by ex-
amining the vasorelaxant properties of vardenaﬁl, we dem-
onstrated that vardenaﬁl potently caused pulmonary artery
relaxation in a dose-dependent fashion through mechanisms
involving both NO/cGMP-dependent and -independent
pathways.
Pulmonary arterial hypertension is characterized by
increased pulmonary vascular resistance, narrowing of pul-
monary vascular lumen due to thickening of the vessel
media, changes in functional parameters of the lung vascu-
lature, and right ventricular hypertrophy [21]. In our study,
pulmonary hypertension model was established with the
development of right ventricular hypertrophy. Speciﬁcally,
we used the ratio of the weight of the right ventricle (RV)
to the weight of the left ventricle plus septum (RV/(LV+S))
which was found to be a reliable index of right ventricular
h y p e r t r o p h yi np r e v i o u ss t u d i e s[ 22–24]. The present study
showed that the arterial medial thickening in the pulmonary
vasculature was signiﬁcantly increased in the MCT group
























































Figure 3: Eﬀects of L-NAME (10
−4 M; n = 15) and ODQ (10
−5 M;
n = 15) on the relaxations induced by vardenaﬁl in control
(a) and pulmonary hypertension group (b). Data were calculated
relative to the maximal changes from the contraction produced by
phenylephrine (10
−6 M) in each ring, which was taken as 100%.
∗P<0.05 as compared with control.
as well as the increase in right ventricular hypertrophy. In
this way, pulmonary hypertension is evidenced with these
morphological changes in our experimental model.
Although the underlying mechanisms of PAH have not
beenfullyelucidated,ithasbeenshownthatvasodilatorther-
apies including PDE-5 inhibition, can reduce the increase
in pulmonary vascular resistance and cause vasodilatation.
[25, 26]. When compared with expression of PDE-5 in other
tissues such as myocardium, the expression and activity
of PDE-5 is considerably higher in lung and pulmonary
vascular smooth muscle cells [8]. Phosphodiesterase type-
































Figure 4: Concentration-response curves to CaCl2 in the absence
or presence of vardenaﬁl (10−7–10−6 M; n = 13) in pulmonary
hypertensive rat pulmonary artery rings. Data were calculated
relative to the maximal changes from the contraction produced by
KCl (80mM) in each ring, taken as 100%. ∗P<0.05 as compared
with control.
beneﬁcial eﬀects in PAH. Moreover, sildenaﬁl and tadalaﬁl
are currently approved for the treatment of PAH. In light
of the foregoing, we aimed to investigate the eﬀects of other
commercially available PDE-5 inhibitor, vardenaﬁl, in MCT-
induced pulmonary artery hypertension.
Our ﬁndings conﬁrm that vardenaﬁl is an eﬀective
pulmonary vasodilator and the incubation with NO-cGMP
pathway inhibitors (L-NAME or ODQ) attenuates the va-
sodilator action of vardenaﬁl. This ﬁnding is in agreement
with previous studies in that PDE-5 is implicated in the
process via inactivating cGMP [27]. Besides these incuba-
tions, pulmonary hypertension also decreased the relaxation
responses of vardenaﬁl in our study, and it caused marked
rightward shifts in the curves to vardenaﬁl. But, maximal
responses to vardenaﬁl were not aﬀected with incubations
or pulmonary hypertension. Our ﬁndings indicated that var-
denaﬁl, in addition to inhibiting PDE-5 and provoking pul-
monary artery relaxation via NO-cGMP-dependent mecha-
nisms, also evokes activation of some NO-cGMP-independ-
ent mechanisms. Recently, vardenaﬁl was shown in a twelve-
week, randomized, double-blind, placebo-controlled study
involving 66 patients to improve 6-minute walking distance
and pulmonary hemodynamic [28]. In that study, vardenaﬁl
was associated with only mild and transient adverse events.
But clinicians should be aware of the hypotension occurring
risk as a class eﬀect of PDE-5 inhibitors in combination with
nitrates [29].
Calcium (Ca+2) inﬂux through channels represents one
of the major pathways to control the vascular tone [30]. Its
blockade causes vasorelaxation or inhibits the vasocontrac-
tion. Hence, we sought to investigate eﬀects of vardenaﬁl on
contractionsinducedbyCaCl2 inCa+2-freemedium.Atcon-
centrations 10−7 and 10−6 M, vardenaﬁl shifted the curves
for CaCl2 to the right along with signiﬁcant reductions in
maximal responses. Our ﬁndings simply suggest that, at least
in the concentrations employed in this study, vardenaﬁl in-
hibitstheexternalCa+2 entry.Thispossibilityisinagreement
with previous studies demonstrating that vardenaﬁl, but not
sildenaﬁl or tadalaﬁl, aﬀects Ca+2 handling with its Ca+2-
channel blocking activity in the rat aorta, in addition to
rabbitpulmonaryarteryandhumanwashedplatelets[7,27].
In conclusion, the data reported herein show that varde-
naﬁl potently relaxes pulmonary artery rings through NO-
cGMP-dependent and -independent mechanisms. In addi-
tion, vardenaﬁl-induced relaxations seem to involve block-
ade of Ca+2 entries. The results in this suggest that vardenaﬁl
may be more eﬀective than sildenaﬁl and tadalaﬁl for the
treatment of pulmonary hypertension. Also, the clinical im-
plications of this research require further randomized,
placebo-controlled studies to precisely deﬁne the long-term
eﬃcacy, side eﬀects, and drug interactions of vardenaﬁl in
order to emphasize its place in the management of PAH.
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